1. PD-L1 expression and its prognostic value in metastatic papillary renal cell carcinoma: Results from a GETUG multicenter retrospective cohort.
- Author
-
Naffrichoux, Jérémie, Poupin, Pierre, Pouillot, William, Linassier, Claude, Rioux-Leclercq, Nathalie, De Vries-Brilland, Manon, Mourey, Loïc, Laguerre, Brigitte, Oudard, Stéphane, Gross-Goupil, Marine, Mousset, Coralie, Gravis, Gwenaelle, Rolland, Frédéric, Moise, Laura, Emambux, Sheik, Vassal, Cécile, Zanetta, Sylvie, Penel, Nicolas, Albiges, Laurence, and Fromont, Gaëlle
- Subjects
- *
THERAPEUTIC use of antineoplastic agents , *STATISTICAL correlation , *CANCER invasiveness , *PROGRAMMED death-ligand 1 , *PAPILLARY carcinoma , *RARE diseases , *TUMOR markers , *RETROSPECTIVE studies , *DISEASE prevalence , *MULTIVARIATE analysis , *NEOVASCULARIZATION inhibitors , *GENE expression , *METASTASIS , *IMMUNE checkpoint inhibitors , *IMMUNOHISTOCHEMISTRY , *RENAL cell carcinoma , *RESEARCH , *PROTEIN-tyrosine kinases , *SURVIVAL analysis (Biometry) , *PATHOLOGIC neovascularization , *IMMUNITY , *OVERALL survival , *PHARMACODYNAMICS - Abstract
Papillary renal cell carcinoma (pRCC) is a rare and aggressive cancer with no specifically established therapeutic strategy in the metastatic setting. Combinations of tyrosine kinase and immune checkpoint inhibitors (ICI) are a promising option. We aimed to study the immune landscape of metastatic pRCC, and its interactions with angiogenesis pathways, to search for potential therapeutic targets. The expression of immune markers (PD-L1, PD-1, PD-L2, LAG-3) and angiogenic pathways (CAIX, c-MET), was analyzed by immunohistochemistry on 68 metastatic pRCC retrieved from a retrospective multicenter GETUG cohort. Our primary endpoint was to estimate the prevalence of PD-L1 expression and its prognostic impact in metastatic pRCC. Secondary endpoints included the evaluation of other immune markers (PD-1, PD-L2, and LAG-3) and their association with PD-L1. We also assessed angiogenic markers and their association with PD-L1. Overall, 27.9 % of tumors were PD-L1 positive. PD-L2 was more frequently expressed (45.6 %), PD-1 and LAG-3 were positive in 17.6 % and 19.1 % respectively. None of these markers was correlated with PD-L1 expression. 66 % (45/68) expressed at least one immune marker, and 43 % (29/68) were "double-positive", as they expressed both immune and angiogenic markers. OS was significantly shorter for patients with PD-L1 positive pRCC. A multivariate analysis confirmed a significant association between PD-L1 expression and shorter overall survival (HR = 4.0, p = 0.01). These results reinforce clinical data on the expected benefit of ICI in metastatic pRCC treatment, as PD-L1 expression is a factor of poor prognosis in this multicenter cohort. • 28 % of the 68 metastatic papillary renal cell carcinoma (pRCC) were PD-L1 positive. • pRCC expressing PD-L1 had a poorer metastatic overall survival. • 43 % of the pRCC were "double positive", expressing immune and angiogenic markers. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF